Skip to main content
Premium Trial:

Request an Annual Quote

Millennium, Compugen Ink Protein-Pathway R&D Collaboration

NEW YORK, March 20 - Compugen and Millennium Pharmaceuticals on Wednesday said they plan to co-develop software that can help researchers predict protein pathways that could be used in drug discovery and development.

 

Terms of the open-ended deal, announced on Wednesday, call for Compugen to apply its bioinformatics platform to Millennium's high-throughput technologies, especially its transcriptional profiling tools.

 

Though financial details of the collaboration were not disclosed, Compugen said that each partner will share the costs as well as the rights "to certain aspects" of the technology they develop.

 

The products that the partners hope to develop "are more general research tools" that can be used in a variety of disease applications, Mor Amitai, president and CEO of Compugen, said.

 

No other details were provided by a statement, and Amitai remained mum on specific aspects of the collaboration.

The Scan

Tennessee's COVID-19 Sequencing

The Tennessean reports that a state lab there can now run its own genome sequencing analyses of SARS-CoV-2 samples.

Sanction Violation Charges

A former professor has been charged with exporting genetic sequencing equipment to Iran in violation of US sanctions, the Miami Herald reports.

Prenetics to Go Public Through SPAC

Prenetics, a Hong Kong-based genomic and diagnostic company, is going public through a SPAC merger, according to 360Dx.

Nature Papers Examine Genomes of Centenarians, Transcription-Coupled DNA Repair

In Nature this week: analysis of centenarian genomes uncovers longevity-linked variants, and more.